Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Aardvark Therapeutics (NASDAQ: AARD) faces a securities class action alleging its Feb. 13, 2025 IPO offering documents and subsequent disclosures negligently overstated ARD-101’s safety and clinical/regulatory/commercial prospects. The complaint claims ARD-101 was “less safe” than investors were led to believe and that related statements were materially false or misleading during the Feb. 13, 2025–May 14, 2026 class period. While the filing is not an outcome, the allegations could weigh on investor sentiment toward the company and its disclosures.

Analysis

This is less a headline-legal event than a funding-cost event. For a development-stage biotech, any credible safety/overstatement allegation raises the discount rate applied to the entire pipeline: partners demand better indemnities, crossover funds mark down probability of future value realization, and retail liquidity tends to disappear faster than the court process moves.

The next 1-3 months matter more than the lawsuit itself because the stock will trade on perceived capital needs. If management has to defend the asset, produce cleaner data, or refinance, the market usually prices in a higher chance of a dilutive raise, weaker partnering leverage, and a longer path to monetization. That is the real second-order damage: even without an adverse ruling, the company may have to pay up for capital or accept less favorable deal terms.

From a relative-value lens, the likely losers are other single-asset, pre-commercial biotech names with similar balance-sheet fragility, which can see a small but persistent multiple discount as investors generalize the risk. The contrarian view is that class-action filings often do not change intrinsic value unless they are paired with fresh clinical/regulatory deterioration; if no new negative data arrives, this may become a tradable overhang rather than a thesis breaker.

For now, this looks more like a financing and sentiment problem than a sector-wide read-through. The key falsifier is any non-dilutive strategic transaction, or a clean data/regulatory update that restores credibility before the market starts pricing in a raise.

Key Decisions for Investors

• Short AARD on any post-news strength over the next 1-4 weeks; use tight risk controls because borrow/liquidity may be the binding constraint. Expect the trade to work through lower confidence in future financing rather than through the lawsuit timeline itself.
• If listed options are liquid, buy 1-3 month AARD put spreads instead of outright puts to capture the litigation/capital-overhang drift while capping premium spend. Risk/reward is favorable if the stock grinds lower on analyst/model revisions.
• Pair trade: short AARD vs long XBI for a 1-3 month catalyst window to isolate idiosyncratic legal and financing risk from biotech beta. Cover if the company announces a strategic partnership or non-dilutive financing.
• Set an alert for any ATM/secondary filing or debt financing over the next 6 months; that is the higher-probability value transfer event than the court case itself. If financing terms are cleaner than expected, the bearish thesis weakens materially.